QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
NASDAQ:NAUT

Nautilus Biotechnology (NAUT) Stock Forecast, Price & News

$3.46
-0.05 (-1.42%)
(As of 09/21/2023 ET)
Compare
Today's Range
$3.42
▼
$3.60
50-Day Range
$2.87
▼
$3.94
52-Week Range
$1.50
▼
$4.65
Volume
65,928 shs
Average Volume
106,421 shs
Market Capitalization
$432.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Nautilus Biotechnology MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
73.4% Upside
$6.00 Price Target
Short Interest
Bearish
1.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.64) to ($0.81) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.71 out of 5 stars

Medical Sector

841st out of 961 stocks

Analytical Instruments Industry

24th out of 27 stocks

See Top Rated MarketRank™ Stocks Here

NAUT stock logo

About Nautilus Biotechnology (NASDAQ:NAUT) Stock

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was incorporated in 2016 and is headquartered in Seattle, Washington.

NAUT Price History

NAUT Stock News Headlines

September 16, 2023 | americanbankingnews.com
Nautilus Biotechnology (NASDAQ:NAUT) Shares Up 12.3%
September 8, 2023 | wsj.com
Nautilus Biotechnology Inc.
September 21, 2023 | Chaikin Analytics (Ad)
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
September 6, 2023 | finance.yahoo.com
Nautilus Biotechnology to Participate in Upcoming September Investor Conferences
August 17, 2023 | finance.yahoo.com
With 33% ownership, Nautilus Biotechnology, Inc. (NASDAQ:NAUT) insiders have a lot riding on the company's future
August 3, 2023 | msn.com
Silicon Valley's biotech sector is still going strong amid concerns about economy
August 3, 2023 | axios.com
Silicon Valley's biotech sector is still going strong
August 2, 2023 | finanznachrichten.de
Nautilus Biotechnology Inc.: Nautilus Biotechnology Reports Second Quarter 2023 Financial Results
September 21, 2023 | Investor Place Media (Ad)
Disturbing Truth About Biden's New Program To Seize Your Cash
A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
August 2, 2023 | msn.com
Marcus GAAP EPS of $0.35 beats by $0.06, revenue of $207M beats by $8.27M
August 2, 2023 | msn.com
Nautilus Biotechnology GAAP EPS of -$0.13 beats by $0.01
July 26, 2023 | benzinga.com
Spectrometry Market is Rising at 7.1% CAGR to Surpass US$ 37.55 Billion by 2033: Fact.MR Report
July 11, 2023 | finance.yahoo.com
Nautilus Biotechnology to Announce Second Quarter Financial Results on August 2, 2023
June 28, 2023 | finance.yahoo.com
Despite Nautilus Biotechnology's Pullback, Insiders Still Gained US$167k
May 18, 2023 | finance.yahoo.com
Nautilus Biotechnology (NASDAQ:NAUT) Is In A Good Position To Deliver On Growth Plans
May 3, 2023 | finance.yahoo.com
Q1 2023 Nautilus Biotechnology Inc Earnings Call
April 23, 2023 | seekingalpha.com
Nautilus Biotechnology: The Rubber Will Soon Meet The Road
April 18, 2023 | finance.yahoo.com
Nautilus Biotechnology to Announce First Quarter Financial Results on May 2, 2023
March 7, 2023 | finance.yahoo.com
Nautilus Biotechnology Announces “First Access Challenge” Winners
March 1, 2023 | insidermonkey.com
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2022 Earnings Call Transcript
February 23, 2023 | finanznachrichten.de
Nautilus Biotechnology Inc.: Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2022 Financial Results
February 23, 2023 | msn.com
Nautilus Biotechnology GAAP EPS of -$0.11 beats by $0.03
January 26, 2023 | finance.yahoo.com
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
January 24, 2023 | seekingalpha.com
NAUT Nautilus Biotechnology, Inc.
November 1, 2022 | msn.com
Recap: Nautilus Biotechnology Q3 Earnings
November 1, 2022 | finance.yahoo.com
Nautilus Biotechnology Reports Third Quarter 2022 Financial Results
October 5, 2022 | finance.yahoo.com
Nautilus Biotechnology to Announce Third Quarter 2022 Financial Results on November 1, 2022
See More Headlines
Receive NAUT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nautilus Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

NAUT Company Calendar

Last Earnings
8/02/2023
Today
9/21/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NAUT
CUSIP
N/A
CIK
1808805
Web
www.nautilus.bio
Phone
206-333-2001
Fax
N/A
Employees
153
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+73.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.47)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-57,920,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-18.89%
Return on Assets
-16.81%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
21.13
Quick Ratio
21.13

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.53 per share
Price / Book
1.37

Miscellaneous

Outstanding Shares
124,930,000
Free Float
71,835,000
Market Cap
$432.26 million
Optionable
Optionable
Beta
1.18
13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Sujal M. PatelMr. Sujal M. Patel (Age 48)
    Co-Founder, CEO, Pres, Sec. & Director
    Comp: $501.2k
  • Dr. Parag Mallick Ph.D. (Age 45)
    Co-Founder, Chief Scientist & Director
    Comp: $400k
  • Ms. Anna MowryMs. Anna Mowry (Age 40)
    CFO & Treasurer
    Comp: $467.57k
  • Ms. Gwen E. Weld (Age 65)
    Chief People Officer
    Comp: $390.97k
  • Ms. Mary E. Godwin (Age 64)
    Sr. VP of Operations
  • Mr. Matthew B. Murphy ESQ.Mr. Matthew B. Murphy ESQ. (Age 58)
    Gen. Counsel
  • Mr. Chris Blessington
    VP of Corp. Marketing & Communications
  • Mr. Nick A. Nelson (Age 40)
    Chief Bus. Officer & Sr. VP of Bus. Devel.
  • Dr. Subra Sankar Ph.D. (Age 64)
    Sr. VP of Product Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













NAUT Stock - Frequently Asked Questions

Should I buy or sell Nautilus Biotechnology stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nautilus Biotechnology in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NAUT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NAUT, but not buy additional shares or sell existing shares.
View NAUT analyst ratings or view top-rated stocks.

What is Nautilus Biotechnology's stock price forecast for 2023?

1 equities research analysts have issued 1 year target prices for Nautilus Biotechnology's stock. Their NAUT share price forecasts range from $6.00 to $6.00. On average, they predict the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 73.4% from the stock's current price.
View analysts price targets for NAUT or view top-rated stocks among Wall Street analysts.

How have NAUT shares performed in 2023?

Nautilus Biotechnology's stock was trading at $1.80 at the beginning of the year. Since then, NAUT stock has increased by 92.2% and is now trading at $3.46.
View the best growth stocks for 2023 here.

When is Nautilus Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our NAUT earnings forecast.

How were Nautilus Biotechnology's earnings last quarter?

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) issued its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.04.

What is Nautilus Biotechnology's stock symbol?

Nautilus Biotechnology trades on the NASDAQ under the ticker symbol "NAUT."

Who are Nautilus Biotechnology's major shareholders?

Nautilus Biotechnology's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.89%), Geode Capital Management LLC (0.81%), State Street Corp (0.75%), Northern Trust Corp (0.43%), Sentinel Trust Co. LBA (0.22%) and Nuveen Asset Management LLC (0.15%). Insiders that own company stock include Anna Mowry, Gwen E Weld, Life Sciences Maste Perceptive, Matthew B Murphy, Matthew L Posard, Matthew S Mcilwain, Perceptive Advisors Llc, Subramanian Sankar and Sujal M Patel.
View institutional ownership trends.

How do I buy shares of Nautilus Biotechnology?

Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nautilus Biotechnology's stock price today?

One share of NAUT stock can currently be purchased for approximately $3.46.

How much money does Nautilus Biotechnology make?

Nautilus Biotechnology (NASDAQ:NAUT) has a market capitalization of $432.26 million. The company earns $-57,920,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis.

How many employees does Nautilus Biotechnology have?

The company employs 153 workers across the globe.

How can I contact Nautilus Biotechnology?

Nautilus Biotechnology's mailing address is 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003. The official website for the company is www.nautilus.bio. The company can be reached via phone at 206-333-2001 or via email at investorrelations@nautilus.bio.

This page (NASDAQ:NAUT) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -